Evaluation of aromatase as a potential biomarker and its association with CA 15-3 in patients with non-metastatic breast cancer
Keywords:
Breast cancer, Aromatase, CA 15-3, TumorAbstract
Breast cancer has been more common among Iraqi women in recent years. Monitoring proteins in human bodily fluids for early stage detection and prognosis of breast cancer is the best way and the first step toward effective therapy, delaying metastases and lowering mortality. In this study, we aimed to evaluate the value of Aromatase as a diagnostic and prognostic marker in breast cancer patients and to analyze the associations between Aromatase and standard CA 15-3 biomarker, as well as clinicopathological parameters. This study included 60 newly diagnosed patients, 49 receiving adjuvant hormone therapy, and 50 women who had a benign breast tumour as controls. We measured the serum levels by ELISA technique of Aromatase and CA 15-3. The results showed there were a significant difference in the mean serum Aromatase level amongst study groups (p < 0.001), and showed significant positive correlation with serum CA 15-3 in newly diagnosed group and treated group, (P < 0.001) and (p = 0.041), respectively. It also showed there were no significant correlations of serum Aromatase and CA 15-3 with menopause status, age, BMI, tumor size, node status, grade, tumor type, ER, PR and Her2.
Downloads
References
Abd-Allateef, M. W., Hassan, F. A.-A. and Saleh, W. A. (2016) ‘Study the Effect of Anastrozole on Estradiol and Cytochrome P450 (Aromatase Enzyme) in Postmenopausal Breast Cancer Patients’, Journal of Al-Nahrain University-Science, 19(2), pp. 43–50. doi: 10.22401/jnus.19.2.06.
Abed, S. N. et al. (2020) ‘Serum levels of cancer antigen 15.3 and estrogen in a samples of iraqi women with breast cancer treated with anastrazole’, International Journal of Pharmaceutical Research, 12(August), pp. 1604–1608. doi: 10.31838/ijpr/2020.SP1.246.
Armasu, I. et al. (2020) ‘Insights on aromatase immunohistochemistry: Variations between intrinsic molecular subtypes of breast cancers’, Acta Endocrinologica, 16(1), pp. 22–29. doi: 10.4183/aeb.2020.22.
Attia, M. S. et al. (2021) ‘Terbium bipyridyl complex as a photo probe for the determination of carbohydrate antigen CA15.3 in different breast cancer patient samples’, Egyptian Journal of Chemistry, 64(7), pp. 3541–3546. doi: 10.21608/ejchem.2021.66294.3421.
Bonechi, M. et al. (2018) ‘Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy’, Oncotarget, 9(23), pp. 16389–16399. doi: 10.18632/oncotarget.24700.
Brown, K. A. et al. (2017) ‘Menopause is a determinant of breast aromatase expression and its associations with BMI, inflammation, and systemic markers’, Journal of Clinical Endocrinology and Metabolism, 102(5), pp. 1692–1701. doi: 10.1210/jc.2016-3606.
Choudhury, C. R. and Agarwala, N. (2018) ‘A Study of Correlation of Pre-operative Serum CA-15.3 with Respect to Prognostic Factors and Early Recurrence in Breast Carcinoma in A Tertiary Care Centre in India’, International Journal of Contemporary Medical Research [IJCMR], 5(10). doi: 10.21276/ijcmr.2018.5.10.12.
Clatot, F. et al. (2020) ‘Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer’, Breast Cancer Research, 22(1), pp. 1–12. doi: 10.1186/s13058-020-01290-x.
Coppola, L. et al. (2021) ‘The impact of different preanalytical methods related to CA 15-3 determination in frozen human blood samples: a systematic review’, Systematic Reviews, 10(1), pp. 1–11. doi: 10.1186/s13643-021-01631-7.
Duffy, M. J. (2006) ‘Serum tumor markers in breast cancer: Are they of clinical value?’, Clinical Chemistry, 52(3), pp. 345–351. doi: 10.1373/clinchem.2005.059832.
Friesenhengst, A. et al. (2018) ‘Elevated Aromatase (CYP19A1) Expression Is Associated with a Poor Survival of Patients with Estrogen Receptor Positive Breast Cancer’, Hormones and Cancer, 9(2), pp. 128–138. doi: 10.1007/s12672-017-0317-2.
Hameed, E. H., Hussein, S. Z., & Abed, N. A. (2018) ‘Evaluation Of Aromatase Activity In Pre And Postmenopausal’, WJPMR, 4(9), pp. 99–100.
Hasanzadeh, M. et al. (2018) ‘Ultrasensitive immunoassay of tumor protein CA 15.3 in MCF-7 breast cancer cell lysates and unprocessed human plasma using gold nanoparticles doped on the structure of mesoporous silica’, International Journal of Biological Macromolecules, 120, pp. 2493–2508. doi: 10.1016/j.ijbiomac.2018.09.020.
Hassanpour, S. et al. (2019) ‘A novel paper based immunoassay of breast cancer specific carbohydrate (CA 15.3) using silver nanoparticles-reduced graphene oxide nano-ink technology: A new platform to construction of microfluidic paper-based analytical devices (μPADs) towards biomedical analysis’, Microchemical Journal, 146(January), pp. 345–358. doi: 10.1016/j.microc.2019.01.018.
Kanomata, N. et al. (2017) ‘Preparation of a novel antiserum to aromatase with high affinity and specificity: Its clinicopathological significance on breast cancer tissue’, PLoS ONE, 12(5), p. 183202. doi: 10.1371/journal.pone.0177439.
Li, J. et al. (2020) ‘Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype: a cohort study’, Breast Cancer, 27(4), pp. 621–630. doi: 10.1007/s12282-020-01058-3.
Li, Y., Wei, R. and Song, S. (2018) ‘Diagnostic and Prognostic Value of Serum Thymidine Kinase 1 in Cancer Patients’, Indian Journal of Hematology and Blood Transfusion, 34(1), pp. 168–170. doi: 10.1007/s12288-017-0812-1.
Park, B. W. et al. (2008) ‘Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes’, Annals of Oncology, 19(4), pp. 675–681. doi: 10.1093/annonc/mdm538.
Pedersen, A. C. et al. (2013) ‘Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer’, Clinical Chemistry and Laboratory Medicine, 51(7), pp. 1511–1519. doi: 10.1515/cclm-2012-0488.
Ragab, H. M. et al. (2018) ‘Assessment of Ki-67 as a potential biomarker in patients with breast cancer’, Journal of Genetic Engineering and Biotechnology, 16(2), pp. 479–484. doi: 10.1016/j.jgeb.2018.03.002.
Reyes-Vázquez, L., Hernández, A. J. A. and Calderón-Aranda, E. S. (2020) ‘Role of aromatase activation on sodium arsenite-induced proliferation, migration, and invasion of MDA-MB-231 and MDA-MB-453 breast cancer cell lines’, Toxicology, 437(September 2019), p. 152440. doi: 10.1016/j.tox.2020.152440.
Robertson, J. F. R. et al. (2021) ‘Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer’, European Journal of Cancer, 145, pp. 19–28. doi: 10.1016/j.ejca.2020.11.038.
Saadati, A. et al. (2019) ‘Immunosensing of breast cancer tumor protein CA 15-3 (carbohydrate antigen 15.3) using a novel nano-bioink: A new platform for screening of proteins in human biofluids by pen-on-paper technology’, International Journal of Biological Macromolecules, 132, pp. 748–758. doi: 10.1016/j.ijbiomac.2019.03.170.
Santen, R. J. et al. (2009) ‘History of aromatase: Saga of an important biological mediator and therapeutic target’, Endocrine Reviews, 30(4), pp. 343–375. doi: 10.1210/er.2008-0016.
Sung, H. et al. (2021) ‘Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries’, CA: A Cancer Journal for Clinicians, 71(3), pp. 209–249. doi: 10.3322/caac.21660.
Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). Get vaccinated when it is your turn and follow the local guidelines. International Journal of Health Sciences, 5(3), x-xv. https://doi.org/10.53730/ijhs.v5n3.2938
Tarighati, E., Keivan, H., & Mahani, H. (2022). A review of prognostic and predictive biomarkers in breast cancer. Clinical and Experimental Medicine, 1-16.
Thaib, P. K. P., & Rahaju, A. S. (2022). Clinicopathological profile of clear cell renal cell carcinoma. International Journal of Health & Medical Sciences, 5(1), 91-100. https://doi.org/10.21744/ijhms.v5n1.1846
Zhao, H. et al. (2018) ‘Adiposity Results in Metabolic and Inflammation Differences in Premenopausal and Postmenopausal Women Consistent with the Difference in Breast Cancer Risk’, Hormones and Cancer, 9(4), pp. 229–239. doi: 10.1007/s12672-018-0329-6.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
